Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It’s possible the numbers are placeholders, I’m going from my (fairly extensive!) direct experience. You wouldn’t need to convert the ‘Latin’. You’d only use that for setting up a template/style sheet - which is why I’m saying It’s more likely to be the real thing (at least everything except the numbers) In favour of the argument that the numbers could be placeholders is that whoever is writing the copy may not have been given that information as yet.
@PL
It doesn't match up:
Conclusions: The colloidal gold immunochromatography assay for SARS-Cov-2 specific IgM/IgG anti-body had 71.1% sensitivity and 96.2% specificity in this population, showing the potential for a useful rapid diagnosis test for COVID-19. Further investigations should be done to evaluate this assay in variety of clinical settings and populations.
Yes it seems to have a number of contradictions.... very confusing ! I’m of the view that this is a dummy run so I’m not going to take the figures quoted too seriously. Nice to see some activity though ... but I really hope they do a better job with the final version when it’s ready !!!
https://pubmed.ncbi.nlm.nih.gov/32355546/
A saliva version of that antibody test... can’t find anything on t’internet about one. Looks like that’s what they’re also going to flog under their brand. Good for them. Sir Al decided it wasn’t a market worth going after.
His brand all over it, yep needs to say something. Affects share price and it’s a contractual partner
Just my 2p, no idea of regulations truth be told
This is an antibody test developed in Spain, not Avacta's
I guess he doesn’t have to say anything as the figures weren’t under AVACTA but a separate paragraph and a separate company ?
Dummy press releases used all the time, stick some figures in so we can test format, update when figures in, especially at launch, other wise you
End up trying to covert pages of Latin. They might be true or not, either way can’t be trusted.
Yes someone might lose their job but is likely to be a a developer filling in for ops who are on holiday. Stuff like this happens all the time, normally it’s a hic up.
Expect to see something from al on Monday. True or not it needs to be clarified.
@JoeyDiamond
I think you've got your wish.
Yes very strange. It describes it as a test to check if you HAVE covid not HAD. Anyway; long weekend of speculation ahead lol
Monday is going to be very interesting but it does indeed look like Medusa are developing another test that is further along than Avacta
Cautious Optimist.... you’ve got me thinking. Maybe there ARE 2 tests..... one at 94/95 as shown on the website and branded Medusa 19 Life Sciences. The other one to have much higher Specificity, at the expense of a little Sensitivity branded Avacta. As a consumer, you choose which you prefer. Behind the scenes though, BOTH tests are produced by Avacta ????
Will be kick in the teeth if it is another test!
An independent clinical study was conducted at Hospital Carlos III in Madrid, Spain
I can just imagine the directors now going f**k stop the website guy now. Whats his telephone number? Quick!! :)
I can still see this all on my mobile
Airports
Offices
at home
factories
school
mmmm
apid Saliva Protein Test (RSPT)
The RSPT is a non-invasive test indicating infection from SARS-CoV-2, the virus underlying COVID-19:
– Provides results on the spot in 10 minutes
– Less intrusive than a swab or blood test
– Simple saliva sample required
– Can be taken on the premises (with a healthcare professional present)
– 94% sensitivity in the early phases of infection
It enables businesses with a healthcare professional present to test on a wide scale and build confidence to return to work quickly and safely.
The RSPT is a colloidal gold immunochromatography test kit and detects the patients immune response to the virus using a patented buffer
solution. This unique buffer can conserve proteins present in saliva which are produced by the body to the presence of the COVID-19 virus.
The lateral flow strip has lines to show whether you have the IgG and IgM antibodies to Covid-19 viral infection in your saliva. The reagents form lines, much in the same way as a pregnancy test, to reveal whether you are positive or negative for the Covid-19 antibodies.
The test is completed in 10 minutes
In the pack
1 x lateral flow cassette
1 x 3ml Buffer A
1 x 1ml Buffer B
1 x Crytube
1 x Pipette
1 x
Also in "How Accurate is the Test?"
An independent clinical study was conducted at Hospital Carlos III in Madrid, Spain.
150 patients were tested and the following results were achieved :
Snot us :(
Just to speculate even more to the second test been the 3m test. 2 of the employes previously worked for 3m it seems from the our people page. Gonna be a fun weekend of speculation haha
Is it the mole catcher’s website?
Non-invasive (Symbols for each instead of bullets)
Results in 10 minutes
Easy to use
94% sensitivity in asymptomatic patients
The RSPT is a best in class saliva lateral flow test for early detection of SARS-CoV-2 proteins and highly accurate in identifying the virus in asymptomatic patients. Studies suggest 40% of all COVID-19 infections are asymptomatic.
It is currently thought that COVID 19 symptoms typical exists for a period of 14 days but can be longer and you are contagious for a period of 7 – 10 days from infection but again can be longer. The RSPT is highly accurate during this early period of the virus; this early detection and isolation of infected individuals will play a vital role in stopping the further escalation of the pandemic.
The saliva test should not be confused with a blood antibody test using lateral flow devices.
The saliva test detects SARS-CoV-2 at this early stage whilst blood antibody tests detect a lot later in the process.
On comparison of the RSPT against blood antibody tests within our clinical study it was found that saliva detected IgM antibodies much earlier than blood and the accuracy of Rapid Saliva Protein Test is far greater in saliva than in blood in the early phase of the infection (<6 days).
With the RSPT 94% sensitivity was achieved on asymptomatic patients, where as in the same study a blood antibody test only achieved 52% sensitivity.
This is genuine. The whole thing. % figures may be placeholders but as a web developer you don’t use text like this unless it has been given to you:
“Comparable results with a PCR test for asymptomatic patients but without significant discomfort from throat and nasal swab and considerable delay in results.”
Medusa 19 Logo
NEW – Medusa 19 Life Sciences Rapid Saliva Protein Test
Medusa 19 are working with their partner, Medusa 19 Life Sciences, to exclusively bring to market the best in class saliva lateral flow test for early detection of SARS-CoV-2 proteins and highly accurate in identifying the virus in asymptomatic patients.
The Rapid Saliva Protein Test (RSPT) is a simple, non-invasive, on the spot test indicating infection from SARS-CoV-2, the virus underlying COVID-19.
It is a lateral flow test requiring a simple saliva sample, a comfortable and non-invasive collection process, providing rapid results within 10 minutes.
Comparable results with a PCR test for asymptomatic patients but without significant discomfort from throat and nasal swap and considerable delay in results.
94% sensitivity, 95% specificity and 95% accurate
Now I’m baffled, it’s an antibody test, so completely separate to ours